Versalis Acquires Remaining 64% Stake in Novamont from Mater-Bi
April 28, 2023
Versalis, Eni's chemical company, has signed an agreement to acquire the remaining 64% of Novamont held by Mater-Bi (controlled by Investitori Associati II and NB Renaissance), giving Versalis full ownership of Novamont. The deal aims to integrate Novamont's renewable-chemistry platform into Versalis to accelerate capability expansion and decarbonize Versalis' product portfolio; closing is subject to regulatory approvals.
- Buyers
- Versalis
- Targets
- Novamont
- Sellers
- Mater-Bi, Investitori Associati II, NB Renaissance
- Industry
- Manufacturing
- Location
- Piedmont, Italy
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly Acquires Versanis Bio
July 14, 2023
Biotechnology
Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.
-
Biocomposites Takes Minority Stake in Renovos Biologics
July 5, 2023
Biotechnology
Biocomposites has taken a minority equity stake in Renovos Biologics to support development and pre-market approval of the RENOVITE nanoclay therapeutic delivery platform. The investment will give Renovos access to Biocomposites' development expertise and global distribution network; Biocomposites CEO Michael Harris will join Renovos' board.
-
Altaris Capital Acquires Veranova (Johnson Matthey Health business)
June 1, 2022
Pharmaceuticals
Altaris Capital Partners completed the acquisition of Veranova (formerly Johnson Matthey's Health business) from Johnson Matthey PLC for total consideration of up to £325 million, with Johnson Matthey retaining approximately a 30% equity stake. Veranova is a global CDMO focused on specialty and complex active pharmaceutical ingredients (APIs), headquartered in Wayne, Pennsylvania, with roughly 900 employees across seven development and manufacturing sites in North America, Europe and Asia.
-
Novo Holdings Acquires Double-Digit Stake in bioMASON
December 17, 2019
Manufacturing
Novo Holdings A/S made a multimillion-dollar, double-digit equity investment in US-based bioMASON to help commercialize its bacteria-grown biocement masonry products. As part of the deal Anders Spohr of Novo Holdings will join bioMASON's board as the company scales its sustainable concrete alternative for construction and infrastructure markets.
-
Novo Holdings Invests $72 Million in LanzaTech
August 6, 2019
Biotechnology
Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.
-
Bureau Veritas Acquires Versatec Energy B.V.
November 12, 2024
Energy
Bureau Veritas has acquired Versatec Energy B.V., a Netherlands-headquartered technical consultancy specializing in offshore and onshore energy projects. The deal strengthens Bureau Veritas' capabilities in renewables, offshore wind, hydrogen and other low-carbon energy solutions, adding Versatec’s expertise in commissioning, asset due diligence, operational assurance and digital smart solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.